Drugs.com - Clinical Trials

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S...

May 30, 2025 - 05:30
 0
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S...
Read More

Tags:

Previous Article

A concrete proposal rises from the red mud

Next Article

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for ...

Related Posts

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GLISTEN Phase III Trial Results Show Linerixibat Signif...

May 12, 2025  0

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for...

May 28, 2025  0

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirem...

May 12, 2025  0